Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression

Initially described by Shulman in 1974, eosinophilic fasciitis (EF) is a rare fibrosing disorder involving the fascia.1 Patients with EF are often treated with systemic glucocorticoids as a first-line treatment.1 The pathogenesis is unclear; immunophenotyping studies have found involvement of immune-mediated mechanisms involving macrophages and CD8+ T lymphocytes.2 There are increasing reports of cutaneous immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) in cancer therapy.